NovaBay Pharmaceuticals (NBY)
(Delayed Data from AMEX)
$1.94 USD
-0.22 (-10.19%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $2.04 +0.10 (5.15%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NBY 1.94 -0.22(-10.19%)
Will NBY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NBY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NBY
NovaBay Pharmaceuticals (NBY) Shows Fast-paced Momentum But Is Still a Bargain Stock
NBY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for NBY
NovaBay Pharmaceuticals Offers 20% Discounts on Avenova Eyecare Products During Amazon Prime Day
NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million
NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Multiple Avenova Product Promotions
First Phase of Exploration on Foothills Property Confirms Presence of High TiO2 Grades
NioBay Metals Strikes High-Grade TiO2 in Quebec